Fortress biotech, inc. (FBIOP)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Cash Flows from Operating Activities:
Net loss

-101,660

-141,936

-99,836

-71,290

-53,883

-20,386

-37,158

-

-

Net loss on discontinued operations

0

-13,469

-2,323

-

-

-

-

-

-

Gain from disposal of National

0

2,333

0

-

-

-

-

-

-

Loss from continuing operations

-101,660

-130,800

-97,513

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-27,610

-36,360

Reconciliation of net loss to net cash used in operating activities:
Depreciation expense

-

-

-

944

26

23

17

-

-

Stock-based compensation expense

-

-

-

-

-

-

-

-

1,469

Acquired in-process research and development

-

-

-

-

-

-

-

1,043

20,706

Noncash interest expense

-

-

-

0

167

634

536

130

-

Change in fair value of Common Stock warrant liability

-

-

-

-

-

-

-

-

0

Change in fair value of embedded conversion feature

-

-

-

-

-

-

-

-

0

Change in fair value of Preferred Stock warrant liability

-

-

-

-

-

-

-

-

-1,407

Depreciation expense

1,900

1,400

726

-

-

-

-

3

22

Bad debt expense

100

0

-

-

-

-

-

-

-

Amortization expense of intangible asset

-

-

-

0

0

-

-

-

-

Amortization of debt discount

3,321

2,419

3,141

1,466

314

0

0

-

-

Amortization of product revenue license fee

1,174

666

534

-

-

-

-

-

-

Amortization of operating lease right-of-use assets

1,558

0

-

-

-

-

-

-

-

Amortization of product revenue license fee

-

-

-

183

0

0

-

-

-

Amortization of forgivable loans to registered representatives

-

-

-

176

0

0

-

-

-

Amortization of deferred clearing credit

-

-

-

-13

0

0

-

-

-

Stock-based compensation expense

13,188

15,012

13,403

12,128

14,291

5,546

5,902

3,638

-

Common shares issued for 2017 Subordinated Note Financing interest expense

1,474

1,472

-541

-

-

-

-

-

-

Common shares issuable for Opus interest expense

281

0

-

-

-

-

-

-

-

Issuance of common stock for research and development-licenses acquired expense

0

276

-

-

-

-

-

-

-

Deferred tax benefit

-

-

-

-73

0

0

-

-

-

Issuance of subsidiaries' common shares for research and development expenses

-

-

-

-

-

0

0

-

-

Issuance of common stock for research and development expenses

-

-

200

0

0

-

-

-

-

Issuance of common stock for research and development-licenses acquired expense

0

276

0

-

-

-

-

-

-

Issuance of partner company's common shares for research and development expenses

90

0

50

0

0

-

-

-

-

Change in fair value of subsidiaries' assets and liabilities

-

-

104

1,034

0

-

-

-

-

Change in fair value of subsidiaries' assets and liabilities

-

-

104

1,034

0

-

-

-

-

Common shares issuable for 2017 Subordinated Note Financing interest expense

500

495

500

-

-

-

-

-

-

Recovery of doubtful accounts

-

-

-

47

0

0

-

-

-

Noncash interest expense

-

-

-

-

-

-

-

-

0

Noncash interest expense-related parties

-

-

-

-

-

-

-

-

0

Contribution of services by stockholder

-

-

-

-

-

-

-

-

30

Common shares issuable for 2017 Subordinated Note financing interest expense

-

-

-

1,682

0

0

-

-

0

Common shares issuable for PIK interest expense

-

-

-

0

0

-

-

-

-

Common shares issued for 2017 Subordinated Note financing interest expense

-

-

-

0

0

-

-

-

-

Common shares issued for Opus interest expense

381

859

0

-

-

-

-

-

-

Financing fees on subsidiaries' Convertible Note, at fair value

-

-

-

-

-

0

-

-

-

Change in fair value of investments

0

-1,390

226

-1,071

-1,675

942

0

0

-

Change in fair value of derivative liability

27

682

368

1,039

438

0

-

-

-

Loss on write off of investment

-

-

250

0

0

-

-

-

-

Change in fair value of contingent consideration payable

-

-

-

-

-

0

-

-

-

Change in fair value of derivative liabilities

-

-

-

-

-

-

0

-

-

Change in fair value of partner company convertible note

0

437

-457

-78

0

-

-

-

-

Change in fair value of partner company convertible note

0

437

-457

-78

0

0

-

-

-

Gain on deconsolidation of Caelum

-18,476

0

-

-

-

-

-

-

-

Research and development-licenses acquired, expense

6,000

3,774

4,164

3,838

11,406

0

0

-

-

Asset impairment loss

-

-

-

-

-

722

0

0

-

Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:
Cash deposits with clearing organizations

-

-

-

0

0

-

-

-

-

Accounts receivable

8,141

-2,260

5,928

1,830

0

0

-

-

-

Receivables from broker-dealers and clearing organizations

-

-

-

4,048

0

0

-

-

-

Forgivable loans receivable

-

-

-

84

0

0

-

-

-

Securities owned, at fair value

-

-

-

179

0

0

-

-

-

Inventory

179

507

-32

203

0

0

-

-

-

Other receivables - related party

-1,230

1,477

-1,172

1,634

156

15

-

-

-

Prepaid expenses and other current assets

-1,798

3

4,011

204

739

124

117

238

160

Restricted cash

-

-

-

-

-

0

0

0

-

Other assets

882

17

0

12

0

0

-

-

-

Current assets held for sale

-

-

3,189

-

-

-

-

-

-

Noncurrent assets held for sale

-

-

-620

-

-

-

-

-

-

Current liabilities held for sale

-

-

9,008

-

-

-

-

-

-

Accounts payable and accrued expenses

2,095

4,686

10,651

5,395

5,889

-849

1,184

-260

1,915

Accounts payable and accrued expenses - related party

-149

-23

-

0

0

-

-

-

-

Accounts payable and accrued expenses - related party

-

-

172

-

-

-

-

-

-

Securities sold, but not yet purchased, at fair value

-

-

-

298

0

0

-

-

-

Interest payable - related parties

-

-

-

-

-

-

-

19

-19

Interest payable

8

917

176

61

-1

-81

-10

119

0

Interest payable - related party

-5

-572

602

66

0

0

-

-

-

Lease liabilities

-1,365

0

-

-

-

-

-

-

-

End of term fee associated with Hercules Note

-

-

-

-

-

-398

0

-

-

Other

-

-

-

-

-

-

-

0

-

Other long-term liabilities

749

472

-284

4,346

195

-464

0

-

-

Net cash used in continuing operating activities

-94,961

-97,063

-77,158

-

-

-16,334

-29,646

-23,194

-

Net cash used in discontinued operating activities

0

-1,785

-4,147

-

-

-

-

-

-

Net cash used in operating activities

-94,961

-98,848

-81,305

-45,812

-20,378

-

-

-

-10,952

Cash Flows from Investing Activities:
Purchase of marketable securities, at fair value

-

-

-

0

79,947

20,002

0

-

-

Sale of marketable securities

-

-

-

0

99,949

0

0

-

-

Payment to related parties - CB Pharma Acquisition Corp

-

-

-

-

-

-

0

-

-

Purchase of marketable securities, short-term

-

-

-

-

-

-

-

0

-

Deposit for leasehold improvements

-

-

-

-

-

-

-

-

0

Purchase of research and development licenses

4,650

1,074

3,365

3,785

10,448

-

-

-

3,843

Purchase of long-term investment

-

-

-

-

-

2,925

0

0

-

Purchase of research and development licenses

-

-

-

-

-

0

0

-

-

Purchase of property and equipment

2,345

7,082

648

6,370

283

0

40

54

0

Security deposits paid

-

-

251

6

0

0

-

-

-

Security deposits refund

-

-

42

-

-

-

-

-

-

Security deposits refund

-

-

-

0

22

0

0

-

-

Acquisition of business - National

-

-

-

-4,626

0

-

-

-

-

Deposit for leasehold improvements

-

-

-

-

-

-

148

225

-

Purchase of intangible assets

2,400

1,200

0

350

1,250

0

0

-

-

Purchase of short-term investment (certificates of deposit)

5,000

52,604

56,091

0

0

346

0

0

-

Redemption of short-term investment (certificates of deposit)

22,604

71,002

20,089

0

0

-

-

-

-

Security deposits paid

0

1

-

-

-

-

-

-

-

Deconsolidation of Caelum

-1,201

0

-

-

-

-

-

-

-

Collection on notes receivable

-

-

-

0

0

-

-

-

-

Net cash acquired in acquisition of National Holdings Corp.

-

-

-

-

-

0

-

-

-

Investment in Origo Acquisition Corp.

-

-

-

175

158

0

-

-

-

Net cash provided by (used in) continuing investing activities

7,008

9,041

-40,224

-

-

-23,273

-188

-279

-

Net cash provided by discontinued investing activities

13,089

9,783

0

-

-

-

-

-

-

Net cash provided by (used in) investing activities

20,097

18,824

-40,224

-6,060

7,885

-

-

-

-3,843

Cash Flows from Financing Activities:
Payment of Preferred A dividends

2,559

2,344

299

0

-

-

-

-

-

Proceeds from issuance of Series A preferred stock

6,038

154

25,000

0

0

-

-

-

-

Proceeds from PCP notes payable-related party

-

-

-

-

-

-

-

-

0

Payment of PCP notes payable-related party

-

-

-

-

-

-

-

-

0

Payment of PCP notes payable?TSO asset purchase

-

-

-

-

-

-

-

750

0

Payment of notes payable-related parties

-

-

-

-

-

-

-

-

0

Proceeds from issuance of common stock

-

-

-

-

-

3,502

91,337

28,855

193

Proceeds from notes payable-related parties

-

-

-

-

-

-

-

-

0

Proceeds from issuance of Convertible Preferred Stock Series

-

-

-

-

-

-

-

-

25,784

Payment of costs related to the issuance of Series A preferred stock

578

0

2,804

0

0

32

1,898

2,305

-

Proceeds from at-the-market offering

20,680

7,274

0

434

0

0

-

-

-

Proceeds from issuance of Series A preferred stock for at-the-market offering

812

0

-

-

-

-

-

-

-

Payment of cost related to at-the-market offering

24

0

-

-

-

-

-

-

-

Payment of cost related to issuance of common stock for at-the-market offering

427

257

0

79

0

0

-

-

-

Payment of Hercules Note

-

-

-

-

-

13,654

1,345

0

-

Proceeds from exercise of stock options

-

-

27

0

216

596

970

-

-

Proceeds from partner company's ESPP

123

198

191

189

59

19

92

-

-

Proceeds from partner company's sale of stock

86,180

23,011

95,117

39,662

57,817

0

0

-

-

Payment of costs related to partner company's sale of stock

6,671

343

0

2,844

6,321

0

0

-

-

Proceeds from partner company's at-the-market offering

30,526

7,981

0

-

-

-

-

-

-

Payment of costs related to partner company's at-the-market offering

741

234

0

-

-

-

-

-

-

Assumption of PCP Note related to Asphelia Asset Purchase

-

-

-

-

-

-

-

-

750

Proceeds from exercise of partner company's warrants

0

181

0

-

-

-

-

-

-

Payment of debt issue costs associated with 2017 Subordinated Note Financing

118

404

-

-

-

-

-

-

-

Payment of NSC note

-

-

-

6,392

0

-

-

-

-

Proceeds from 2017 Subordinated Note Financing

-

-

28,355

0

10,000

0

0

-

-

Payment of costs related to the issuance of Common Stock

-

-

-

-

-

-

-

-

0

Cashless Exercise Of Warrants

-

-

-

-

-

-

-

-

0

Payment of debt issuance costs associated with 2017 Subordinated Note Financing

-

-

81

0

855

0

0

288

0

Proceeds from issuance of Hercules Note

-

-

-

-

-

-

-

15,000

0

Proceeds from IDB Note

-

-

-

920

0

14,009

0

-

-

Proceeds from Opus Credit Facility

-

-

2,500

7,000

0

0

-

-

-

Proceeds from 2018 Venture Notes

0

21,707

0

-

-

-

-

-

-

Payment of debt issue costs associated with 2018 Venture Notes

134

1,868

0

-

-

-

-

-

-

Payment of NSC Note

-

-

3,608

-

-

0

-

-

-

Payment of debt issue costs

-

-

0

594

0

9

0

0

0

Proceeds from 2017 Subordinated Note Financing

-

-

-

0

0

-

-

-

-

Payment of debt issuance costs associated with 2017 Subordinated Note Financing

-

-

-

0

0

-

-

-

-

Proceeds from borrowings under line of credit

-

-

-

-

-

-

-

-

0

Payment of line of credit

-

-

-

-

-

-

-

-

0

Proceeds from partner company's Horizon Notes

15,000

0

9,914

4,609

0

-

-

-

0

Payment of debt issuance costs associated with partner company's Horizon Notes

1,393

0

104

-

-

-

-

-

-

Payment of partner company's Convertible Notes

0

4,408

0

-

-

-

-

-

-

Transfer of restricted cash

-

-

-

-

-

-14,586

-

-

-

Net cash provided by continuing financing activities

146,714

50,648

154,208

-

-

-10,155

89,156

40,512

-

Net cash provided by discontinued financing activities

0

0

-3,827

-

-

-

-

-

-

Net cash provided by financing activities

146,714

50,648

150,381

42,905

60,916

-

-

-

23,093

Net (decrease) increase in cash and cash equivalents, cash deposits with clearing organizations and restricted cash

-

-

-

-

-

-49,762

59,322

17,039

8,298

Net (decrease) increase in cash and cash equivalents and restricted cash

71,850

-29,376

28,852

-8,967

48,423

-

-

-

-

Supplemental disclosure of cash flow information:
Cash paid for interest

5,444

4,448

207

-

-

-

-

-

-

Cash paid for interest - related party

456

281

571

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

785

1,387

421

53

Supplemental disclosure of non-cash financing and investing activities:
Settlement of restricted stock units into common stock

2

3

2

-

-

-

-

-

-

Issuance of restricted stock

-

-

-

-

-

4

4

0

0

Issuance of warrants by partner companies' in conjunction with NSC debt

-

-

750

-

-

-

-

-

-

Issuance of warrants by subsidiary in conjunction with NSC debt

-

-

-

-

-

0

0

323

-

Issuance of partner companies'' common shares for settlement

-

-

2,062

-

-

-

-

-

-

Debt discount related to Opus Credit Facility

-

-

201

-

-

-

-

-

-

Beneficial conversion feature related to Opus Credit Facility

-

-

-

-

-

0

-

-

-

Unpaid debt offering costs

26

0

58

-

-

-

-

-

-

Conversion of partner company's notes payable

-

-

314

-

-

-

-

-

-

Common shares issuable for license acquired

164

0

1,682

-

-

-

-

-

-

Common shares issued for 2017 Subordinated Note Financing interest expense

0

500

0

-

-

-

-

-

-

Issuance of partner company warrants in conjunction with Horizon Notes

888

0

-

-

-

-

-

-

-

Common shares issued for Opus debt

500

0

-

-

-

-

-

-

-

Receivables of contribution of capital for 2017 bonuses

0

1,000

0

-

-

-

-

-

-

Unpaid fixed assets

187

196

-

-

-

-

-

-

-

Unpaid at-the-market offering cost

6

0

-

-

-

-

-

-

-

Unpaid Preferred A offering cost

153

0

-

-

-

-

-

-

-

Unpaid research and development licenses acquired

1,350

2,700

-

-

-

-

-

-

-

Unpaid partner company's offering cost

69

0

-

-

-

-

-

-

-

Partner company's previous paid offering cost

833

0

-

-

-

-

-

-

-

Partner company's unpaid intangible assets

4,734

0

-

-

-

-

-

-

-

Goodwill

-

-

-

-18,645

0

-

-

-

-

Accounts receivable

-

-

-

4,889

0

0

-

-

-

Cash deposits with clearing organizations

-

-

-

-1,030

0

0

-

-

-

Receivables from broker-dealers and clearing organizations

-

-

-

-1,607

0

0

-

-

-

Securities owned, at fair value

-

-

-

2,178

0

0

-

-

-

Prepaid expenses and other current assets

-

-

-

1,985

0

0

-

-

-

Property and equipment, net

-

-

-

1,132

0

0

-

-

-

Restricted cash

-

-

-

-353

0

0

-

-

-

Restricted cash

-

-

-

-353

0

-

-

-

-

Accounts payable and accrued expenses

-

-

-

6,079

0

0

-

-

-

Accrued commissions and payroll payable

-

-

-

14,029

0

0

-

-

-

Deferred clearing and marketing credits

-

-

-

-1,007

0

0

-

-

-

Warrants issuable

-

-

-

13,406

0

-

-

-

-

Other current liabilities

-

-

-

707

0

-

-

-

-

Non-controlling interests

-

-

-

17,717

0

0

-

-

-

Non-controlling interests

-

-

-

17,717

0

-

-

-

-

Net cash acquired in acquisition of National Holdings Corp.

-

-

-

4,626

0

0

-

-

-

Fixed assets acquired but not paid

-

-

982

-

-

-

-

-

-

Inter-company costs related to the issuance of Series A preferred stock

6,038

154

-

-

-

-

-

-

-

Unpaid research and development licenses acquired

-

-

755

-

-

-

-

-

-

Goodwill

-

-

-

-18,645

0

0

-

-

-